The sodium–glucose cotransporter 2 inhibitor tofogliflozin prevents diabetic kidney disease progression in type 2 diabetic mice
Zi Li(Juntendo University), Yusuke Suzuki(Juntendo University)
Cited by 13
Related Papers
Association of advanced glycation end products with sarcopenia and frailty in chronic kidney disease
|Scientific Reports|2020|64
Ethnicity and IgA nephropathy: worldwide differences in epidemiology, timing of diagnosis, clinical manifestations, management and prognosis
|Clinical Kidney Journal|2023|55
The role of oxidative stress markers in Indonesian Chronic Kidney Disease (CKD) patients
|Harvard Dataverse|2021|3